{"url_path":"/sec/guts/8-k/2026-07-15/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1572616/0001193125-26-303948-index.html","accession_number":"0001193125-26-303948","cik":"0001572616","ticker":"GUTS","issuer_name":"FRACTYL HEALTH, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1572616/0001193125-26-303948-index.html","primary_entity_key":"0001572616","primary_entity_name":"FRACTYL HEALTH, INC."},"word_count":285,"has_tables":true,"body_markdown":"## Item 7.01 Regulation FD Disclosure.\n\nOn July 15, 2026 Fractyl Health, Inc. (the “Company” or “Fractyl”) issued a press release announcing one-year results from its REMAIN-1 Midpoint Cohort, a distinct patient cohort assessing the potential of the Revita DMR System (“Revita”) to maintain weight loss after GLP-1 discontinuation. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nAs described in the accompanying press release, the Company will host a conference call and live audio webcast today, July 15, 2026 at 8:00 a.m., Eastern Time, to discuss the presentation of data described above.\n\nThe live audio webcast may be accessed through the “Events” section of the Company’s website at ir.fractyl.com. A copy of the presentation to be used by the Company during the conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nThe information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.\n\nThe Company’s website and any information contained on the Company’s website are not incorporated into this Current Report on Form 8-K."}